XENE
XENE clinical trials: Xenon Pharmaceuticals Inc.
Every trial on ClinicalTrials.gov where Xenon Pharmaceuticals Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 23
- Trials linked
- 23
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
XENE on the catalyst calendar · XENE registry changes
- Primary completion Oct 28, 2026ActualPhase 3NCT06775379A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderXenon Pharmaceuticals Inc. · Major Depressive DisorderTerminatedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2033Sponsor estimatePhase 3NCT05718817An Open-label Study of XEN1101 in EpilepsyXenon Pharmaceuticals Inc. · Focal EpilepsyEnrolling by invitationXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 3NCT05716100A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)Xenon Pharmaceuticals Inc. · Focal Onset SeizuresRecruitingXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 3NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresXenon Pharmaceuticals Inc. · Primary Generalized Tonic-Clonic SeizuresRecruitingXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2, 2021ActualPhase 2NCT03796962A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyXenon Pharmaceuticals Inc. · Focal EpilepsyActive, not recruitingXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 3NCT07217860An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)Xenon Pharmaceuticals Inc. · Bipolar DepressionActive, not recruitingXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 3NCT07172516A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)Xenon Pharmaceuticals Inc. · Bipolar DisorderActive, not recruitingXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 3NCT07076407A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)Xenon Pharmaceuticals Inc. · Major Depressive DisorderActive, not recruitingXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 3NCT06922110An Open-Label Study of Azetukalner in Major Depressive DisorderXenon Pharmaceuticals Inc. · Major Depressive DisorderActive, not recruitingXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 18, 2023ActualPhase 2NCT05376150A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderXenon Pharmaceuticals Inc. · Major Depressive DisorderCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2026ActualPhase 3NCT05614063A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresXenon Pharmaceuticals Inc. · Focal Onset SeizuresCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 17, 2023ActualPhase 3NCT04912856An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEEXenon Pharmaceuticals Inc. · EpilepsyTerminatedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 16, 2023ActualPhase 3NCT04639310XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyXenon Pharmaceuticals Inc. · EpilepsyTerminatedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2021ActualPhase 1NCT03340220Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.Xenon Pharmaceuticals Inc. · Healthy VolunteersCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2021ActualPhase 1NCT04952467Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101Xenon Pharmaceuticals Inc. · Healthy VolunteersCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2018ActualPhase 1NCT03467100Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901Xenon Pharmaceuticals Inc. · Healthy VolunteersCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2017ActualPhase 1/Phase 2NCT02656043A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical GelXenon Pharmaceuticals Inc. · Acne VulgarisCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2018ActualPhase 1NCT03468725Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101Xenon Pharmaceuticals Inc. · Healthy Male VolunteersCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2012ActualPhase 1/Phase 2NCT01486446Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With...Xenon Pharmaceuticals Inc. · Primary ErythromelalgiaCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2011ActualPhase 2NCT01195636A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)Xenon Pharmaceuticals Inc. · Postherpetic NeuralgiaCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2009ActualPhase 2NCT00954356Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth ExtractionXenon Pharmaceuticals Inc. · Dental PainCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2010ActualPhase 1/Phase 2NCT01090622Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)Xenon Pharmaceuticals Inc. · Primary ErythromelalgiaCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2009ActualPhase 1NCT00813670Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy VolunteersXenon Pharmaceuticals Inc. · Healthy Human VolunteersCompletedXENELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 23 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner